Spotify
YouTubePresident Trump says the rest of the world is free-riding on American pharmaceutical prices. But what will substantial policy change mean for patients in the US and around the world?
In this episode of A Dose of Economics, Grace Hampson sits down with OHE’s Amanda Cole and global market access consultant Neil Grubert to discuss the biggest developments in U.S drug pricing policy – and what it means for the rest of the world.
They’ll discuss:
- What MFN pricing means in practice
- Implications for drug pricing and market access globally
- What it means for pharmaceutical R&D and innovation long-term
A Dose of Economics is Grace and the Office of Health Economics (OHE) team thinking out loud — debating the questions that matter most in healthcare policy, resource allocation, and health system decision-making, with the experts doing the work at the highest level.
